## SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission

Victor M. Corman<sup>1</sup>, Holger F. Rabenau<sup>2</sup>, Ortwin Adams<sup>3</sup>, Doris Oberle<sup>4</sup>, Markus B. Funk<sup>4</sup>, Brigitte Keller-Stanislawski<sup>4</sup>, Jörg Timm<sup>3</sup>, Christian Drosten<sup>1,5</sup>, Sandra Ciesek<sup>2,5</sup>

<sup>1</sup>Charité University Hospital, Virology, Berlin, Germany

<sup>2</sup>Institute for Medical Virology, University Hospital, Goethe University, Frankfurt, Germany

<sup>3</sup>Institute for Virology, University Hospital Düsseldorf, Faculty of Medicine, University Düsseldorf, Düsseldorf, Germany.

<sup>4</sup>Paul-Ehrlich-Institut, Department Safety of Drugs and Medical Devices, Langen, Germany

Corresponding author:

Markus Funk
Paul-Ehrlich-Institut
Paul-Ehrlich-Straße 51-59, 63225 Langen, Germany
Email: markus.funk@pei.de

<sup>&</sup>lt;sup>5</sup>DZIF, German Centre for Infection Research

Abstract

Oral swabs, sputum and blood samples from 18 patients with SARS-CoV-2 infection were examined using real-time reverse transcription polymerase chain reaction (RT-PCR) testing. Whereas oral swabs or sputum from the lower respiratory tract were tested RT-PCR positive in all patients, RNAemia was neither detected in 3 patients without symptoms nor in 14 patients with flu-like symptoms, fever or pneumonia. The only patient with RNAemia suffered from acute respiratory distress syndrome (ARDS) and was artificially ventilated in an intensive care unit. Risk for SARS-CoV-2 transmission through blood components in asymptomatic SARS-CoV-2 infected individuals therefore seems negligible but further studies are needed.

**Competing Interest Statement** 

The authors have declared no competing interest.

**Ethical approval statement** 

All patients provided informed consent to the use of their data and clinical samples for the purposes of the present study. Institutional review board clearance for the scientific use of patient data has been granted to the treating institution by the Ethikkommission der Medizinischen Fakultät der Ludwig Maximillians Universität München and by the University Hospital's ethics committee, Johann Wolfgang Goethe Universität Frankfurt/Germany.

**Funding Statement** 

This work was funded by the Paul-Ehrlich-Institut (Competent authority/ Germany).

Introduction

As of March 2020, the SARS-CoV-2 pandemic that originated in Wuhan, Hubei Province, China, is

quickly spreading in many countries of the world.

Huang et al. 1 reported RNAemia in 6 of 41 symptomatic Wuhan patients (15%) with laboratory-

confirmed SARS-CoV2 infection. Zhang et al. <sup>2</sup> showed for 15 Wuhan patients diagnosed with viral

pneumonia caused by SARS-CoV-2 that shedding may occur through multiple routes (respiratory,

fecal-oral or body fluids); six out of the 15 patients (40%) were blood positives. In addition, Kim et al.

<sup>3</sup> reported on intermittently positive blood RT-PCR (real-time reverse transcription polymerase chain

reaction) results in 2 SARS-CoV-2 patients in South Korea with mild and moderate symptoms.

In Germany, blood donors have to be at least 18 years old and should not be older than 65 years of

age. In addition, volunteers will not be admitted to blood donation if they show signs and symptoms

of an infection (e.g. fever, flu-like symptoms). With these requirements and the additional donor

screening, a high national safety standard with regard to the prevention of transfusion-related viral

infections has been achieved in recent years 4.

However, with respect to the safety of blood donation, the questions arise whether Corona virus

disease 2019 (Covid-19) can be transmitted through blood and how long SARS-CoV-2 positive

patients with minimal symptoms have to be deferred from blood donation.

**Patients and methods** 

We report on molecular detection of SARS-CoV-2 in 18 patients 2 of whom were infected in China

and evacuated to Germany on February 1  $^{\rm 5}$ . In 16 patients, the transmission in Germany is most

likely<sup>6</sup>. Information on the patient population was published elsewhere<sup>5,6</sup> and SARS-CoV-2 testing

targeting the E and RNA-dependent RNA polymerase gene was performed as previously described by

Corman et al. 7. In patients with minor symptoms, laboratory tests were carried out during the two-

week quarantine period, in those with severe symptoms, tests were done during inpatient treatment.

Results

Twelve of the 18 patients were males and six females. Three patients were asymptomatic, six presented with flu-like symptoms, five had flu-like symptoms as well as fever, two suffered from pneumonia, and one patient needed artificial respiration because of acute respiratory distress syndrome (ARDS) (Table 1). Three of the 18 patients fulfilled the requirements for blood donation in Germany. Whereas oral swabs or sputum from the lower respiratory tract were tested RT-PCR positive in all patients, RNAemia was only detected in one out of seven serum/plasma samples taken from the patient with ARDS.

Discussion

We presented data on 18 SARS-CoV-2 infected patients, 3 patients without specific symptoms and 15 with symptoms of different severity. SARS-CoV-2 genomes were only detected in one of 77 blood samples examined. The patient with RNAemia suffered from ARDS and was artificially ventilated in an intensive care unit. In asymptomatic patients who are eligible for blood donation as well as patients with flu-like symptoms and fever, no SARS-CoV-2 RNA could be detected in the blood or serum despite a clearly positive result in all throat swabs.

Our findings are in line with published data <sup>8</sup> and confirm that SARS-CoV-2 infection may go without noticeable manifestation of clinical symptoms. Furthermore, Chen et al. <sup>9</sup> detected SARS-CoV-2 genome in the blood of 6 out of 57 Chinese patients and found RNAemia to be associated with a more severe clinical picture. In addition, detectable serum SARS-CoV-2 RNAemia was found to be closely linked to an elevated interleukin 6 (IL-6) level in critically ill Covid-19 patients<sup>10</sup>.

Since there is currently no recognized external standardization of the SARS-CoV-2 RT-PCR methods, a direct comparison of the results of Chinese and German studies is not possible. Of note, RNAemia is

not equivalent to infectiousness, i.e. despite the presence of RNA it is unknown whether blood can

harbor intact viruses that are able to infect tissues and, when transfused, can cause hematogenous

transmission.

Hitherto, similarly to the other two coronaviruses that have emerged over the past 20 years (SARS,

the Severe Acute Respiratory Syndrome Coronavirus 11,12 and MERS-CoV, causing Middle East

Respiratory Syndrome<sup>13</sup>, no hematogenous transmissions have been documented for SARS-CoV-2.

Due to a lack of evidence indicating a risk for transfusion transmission of SARS-CoV-2, the American

Association of Blood Banks (AABB), the Food and Drug Association (FDA), and the Centers for Disease

Control and Prevention (CDC) are not recommending any action by blood collection establishments

at this time (March 3, 2020)<sup>14</sup>. Our data support this recommendation.

Conclusion

Among 18 patients with RT-PCR confirmed SARS-CoV-2 infection included in our study only one

critically ill individual had RNAemia. Based on these limited data, there is no measurable risk for

SARS-CoV-2 transmission through blood components in asymptomatic SARS-CoV-2 infected

individuals. As no cases of transmission due to transfusion of blood products have been reported for

SARS, MERS-CoV and SARS-CoV-2, and considering that patients with symptoms of infectious disease

will not be admitted to blood donation in Germany, the risk for transfusion transmission of SARS-

CoV-2 is supposed to be negligible. However, well-powered studies are needed to further evaluate

the potential risk of hematogenous transmission and to determine the appropriate referral time for

blood donation of recovered SARS-CoV-2 patients.

#### **Competing Interest Statement**

The authors have declared no competing interest.

## **Ethical approval statement**

All patients provided informed consent to the use of their data and clinical samples for the purposes of the present study. Institutional review board clearance for the scientific use of patient data has been granted to the treating institution by the Ethikkommission der Medizinischen Fakultät der Ludwig Maximillians Universität München and by the University Hospital's ethics committee, Johann Wolfgang Goethe Universität Frankfurt/Germany.

### **Funding Statement**

This work was funded by the Paul-Ehrlich-Institut (Competent authority/ Germany).

### Acknowledgements

We thank Susanne Müller, Gabriele Ruppert-Seipp and Philipp Berg for technical assistance.

# REFERENCES

- 1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020;**395**(10223):497-506.
- 2. Zhang W, Du R-H, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect 2020;9(1):386-9.
- 3. Kim JY, Ko JH, Kim Y, et al. Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea. J Korean Med Sci 2020;**35**(7):e86.
- 4. Funk MB, Heiden M, Müller S, et al. Haemovigilance Reports of the Paul-Ehrlich-Institut. [March 13, 2020]. Available from: www.pei.de/haemovigilance-report.
- 5. Hoehl S, Rabenau H, Berger A, et al. Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. N Engl J Med 2020.
- 6. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med 2020.
- 7. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020;**25**(3).
- 8. Pan X, Chen D, Xia Y, et al. Asymptomatic cases in a family cluster with SARS-CoV-2 infection. The Lancet Infectious Diseases 2020.
- 9. Chen W, Lan Y, Yuan X, et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerg Microbes Infect 2020;**9**(1):469-73.
- 10. Chen X, Zhao B, Qu Y, et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients, 2020.
- 11. Outbreak of severe acute respiratory syndrome--worldwide, 2003. MMWR Morb Mortal Wkly Rep 2003;**52**(11):226-8.
- 12. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;**348**(20):1967-76.
- 13. Mackay IM, Arden KE. MERS coronavirus: diagnostics, epidemiology and transmission. Virol J 2015;12.
- 14. American Association of Blood Banks (AABB). Coronavirus and Blood donation Talking points. [March 10, 2020]. Available from: http://www.aabb.org/advocacy/regulatorygovernment/Pages/Coronavirus-and-Blood-Donation-Talking-Points.aspx.

Table 1. Molecular detection of SARS-CoV-2 in 18 patients with asymptomatic or symptomatic infection

Patient*	Age	Oral swab**/sputum  qRT-PCR Ct	Blood <sup>#</sup>			No symptoms	Symptoms <sup>##</sup>				
	18 – 65 y		Number of tests performed	Whole Blood qRT-PCR Ct	Serum qRT-PCR Ct	Plasma qRT-PCR Ct	Asymptomatic +/-	Flu-like +/-	Fever +/-	Pneumonia +/-	Art. ventilation ARDS +/-
01	х	30.10	1		1 x neg.		+	-	1	-	-
02	х	24.39	7	4 x neg.	3 x neg.		+	-	i i	-	-
03	х	30.25	7	4 x neg.	3 x neg.		_ §	-	-	-	-
04	х	32.13	6		6 x neg.		-	+	-	-	-
05	х	31.67	7		7 x neg.		-	+	-	-	-
06	х	20.06	1		1 x neg.		-	+	-	-	-
07	х	24.14	2		2 x neg.		-	+	i i	-	-
08	х	27.21	1		1 x neg.		-	+	ï	-	-
09	х	28.46	7		7 x neg.		-	+	1	-	-
10	х	17.44	1		1 x neg.		-	+	-	-	-
11	х	15.35	5	2x neg.	3 x neg.		-	+	+	-	-
12	х	37.32	8		8 x neg.		-	+	+	-	-
13	х	31.05	1		1 x neg.		-	+	+	-	-
14	х	28.43	2	1x neg.	1 x neg.		-	+	+	-	-
15	х	39.1	3		2 x neg.	1 x neg.	-	+	+	-	-
16	х	34.8	2			2 x neg.	-	+	+	+	-
17	х	pos. <sup>§§</sup>	8		4 x neg.	4 x neg.	-	+	+	+	-
18	Х	22.6	8		4 x neg.	3 x neg. <b>1 x pos.</b> \$	-	+	+	+	+

<sup>+</sup> present; - absent; qRT-PCR quantitative reverse transcriptase polymerase chain reaction; Ct cycle threshold; ARDS acute respiratory distress syndrome

<sup>\*16</sup> patients infected in Germany, 2 patients infected in China

<sup>\*\*</sup> Minimum value (max. viral load)

<sup>\*</sup>RNA-NAT-test, method of RdRP (RNA-dependent RNA polymerase gene)-Gene testing according to Corman et al. 6

<sup>##</sup> Symptoms at the time of testing

<sup>&</sup>lt;sup>§</sup> Mild rash on chest and legs, minimal inflammation on throat examination. Afebrile and normal vital signs during hospital observation<sup>4</sup>

<sup>&</sup>lt;sup>5§</sup> SARS-CoV-2 RNA (23.600 copies/ml) was only detected in sputum from the lower respiratory tract.

<sup>5</sup> Low level detection of SARS-CoV-2 RNA (179 copies/ml) in one plasma sample.